Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma

Nakamura, Nobuhiko; Hara, Takeshi; Shibata, Yuhei; Matsumoto, Tomohiro; Nakamura, Hiroshi; Ninomiya, Soranobu; Kito, Yusuke; Kitagawa, Junichi; Kanemura, Nobuhiro; Goto, Naoe; Shiraki, Makoto; Miyazaki, Tatsuhiko; Takeuchi, Tamotsu; Shimizu, Masahito; Tsurumi, Hisashi

doi:10.1007/s00277-015-2499-4

Cited by 87 publications

(58 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Polyploid DLBCL had clinical features that were different from those of DLBCL. The median age of 72.5 years was older than the previously reported median of 57–71 years . In addition, we observed a lower frequency (13 %) of extranodal lesions than a previous study of DLBCL (29 %).…”

Section: Discussioncontrasting

confidence: 75%

“…The median age of 72.5 years was older than the previously reported median of 57-71 years. 23,26,27 In addition, we observed a lower frequency (13 %) of extranodal lesions than a previous study of DLBCL 26 (29 %). Given that six of seven patients treated with chemotherapy survived and showed CR (245-1183 days), polyploid DLBCL may follow a good clinical course and represent a specific clinical characteristic of the disease.…”

Section: Discussioncontrasting

confidence: 72%

See 1 more Smart Citation

Clinical features of diffuse large B‐cell lymphoma with polyploidy

Shimono

Miyoshi

Seto

et al. 2016

Pathology International

View full text Add to dashboard Cite

Polyploidy, defined as more than two sets of homologous chromosomes, is found in a variety of malignant tumors and is thought to be related to disease pathogenesis. However, there have been no studies that have investigated polyploidy in diffuse large B-cell lymphoma (DLBCL). Here we reviewed clinicopathological features of 16 cases of DLBCL with polypoidy, which was defined as DLBCL with either near-tetraploid or greater number of chromosomes as detected by the G-band method. The frequency of polyploid DLBCL was 2.9 % (16/544), including 15 near-tetraploid and one near-pentaploid case. CD5, CD30 and EBER positive cases were 13 % (2/16), 13 % (2/16) and 6 % (1/16), respectively. Bcl2 positive cases were 75 % (12/16). The numbers of huge and multinucleated cells were higher in polyploid than in non-polyploid DLBCL (P = 0.0029 and P < 0.0001, respectively). Clinical features of polyploid DLBCL included reduced infiltration of extranodal sites (2/15, 13 %) and major lymph node infiltration. Of seven cases that received chemotherapy, six responded to treatment and survived. Our results suggest that polyploid DLBCL represents a clinicopathologically characteristic group of DLBCL. This knowledge can be useful for informing more personalized and targeted management of DLBCL patients.

show abstract

Section: Discussioncontrasting

confidence: 75%

Section: Discussioncontrasting

confidence: 72%

Clinical features of diffuse large B‐cell lymphoma with polyploidy

Shimono

Miyoshi

Seto

et al. 2016

Pathology International

View full text Add to dashboard Cite

show abstract

“…In all studies, muscle mass was measured before the start of chemotherapy, and low muscle mass was associated with a worse overall survival compared with patients with normal muscle masses. In one study, the unfavorable survival effect was only detected in males [87].…”

Section: Non-hodgkin Lymphomamentioning

confidence: 95%

“…Three studies described the prognosis of patients with non-Hodgkin lymphoma undergoing chemotherapeutic treatment [63,73,87]. Only one study investigated the association between low muscle mass and treatment tolerability.…”

Section: Non-hodgkin Lymphomamentioning

confidence: 99%

The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature

et al. 2016

View full text Add to dashboard Cite

In several diseases, low muscle mass has been revealed as an unfavorable prognostic factor for outcome.Whether this holds true in patients with solid malignancies as well has increasingly been explored recently. However, this research field is severely hampered by a lack of consensus on how to determine muscle mass in cancer patients and on the definition of low muscle mass. Consequently, the prevalence of low muscle mass varies widely across several studies. Nevertheless, most studies show that, in patients with solid malignancies, low muscle mass is associated with a poor outcome. In the future, more research is needed to get better insight into the best method to determine muscle mass, the exact prognostic value of low muscle mass in diverse tumor types and stages, pathophysiology of low muscle mass in patients with cancer, and ways to intervene and improve muscle mass in patients. This review addresses the current literature on the importance of muscle mass in cancer patients and the methods of muscle measurement. The Oncologist 2016;21:1396-1409 Implications for Practice: An increasing number of studies underline the clinical value of low muscle mass as a prognostic factor for adverse outcomes in cancer patients. However, studies show large heterogeneity because of the lack of a standardized approach to measure muscle mass and the lackof reference populations. As a result, the interpretation of data and further progress are severely hampered, hindering the implementation of muscle measurement in oncological care. This review summarizes the methods of diagnosing low muscle mass in cancer patients, the difference between underlying syndromes such as sarcopenia and cachexia, and the association with clinical outcomes described so far.

show abstract

“…Almost no reports have been published to date regarding EWGSOP or AWGS‐defined sarcopenia in patients with malignant cancer, and muscle mass is frequently assessed by cross‐sectional computed tomography imaging at the L3 vertebra proximal to the psoas muscle. The prevalence of reduced skeletal muscle mass (pre‐sarcopenia) as determined by this method of assessing muscle mass has been reported to be 26–65% among patients with gastric/esophageal cancer, 19–39% among colorectal cancer patients, 11–66% among hepatocellular carcinoma patients, 21–63% among patients with pancreatic cancer, 29–68% among patients with renal cancer, 60–68% among patients with urothelial cancer, approximately 74% among patients with non‐small cell lung cancer and approximately 55% among diffuse patients with large B‐cell lymphoma . The mean age of participants in these studies was approximately 65 years.…”

Section: ▸[B] Epidemiology Of Related Disease Statesmentioning

confidence: 99%